Cardiovascular risk factors of airport visitors in India: results from a nation-wide campaign

Willem J. Verberk Ph.D.1 | Nilesh Goswami MBBS, FFM2

1 CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands
2 Eris Lifesciences Ltd., Ahmedabad, India (Email: nilesh.goswami@erislifesciences.com)

Correspondence
Willem J. Verberk, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht 6229 ER, the Netherlands. Email: Willem.verberk@microlife.ch

Funding information
Eris Foundation an NGO (A non-Government Charitable organization) established the booths in all airports and the one hospital. Eris Lifesciences Ltd. Supported with the logistics of the screening

Abstract
Cardiovascular diseases have become the major cause of death in India, but overall awareness is still low. Therefore, the initiative was undertaken to set up health care screening booths at eight airports and one hospital throughout India to increase awareness and to determine cardiovascular risk factors. Participants were screened for hypertension (systolic blood pressure (BP) \( \geq \) 140 mmHg or diastolic BP \( \geq \) 90 mmHg), diabetes (fasting blood glucose (FBG) level \( \geq \) 126 or \( \geq \) 200 mg/dL for random blood glucose (RBG)), and body mass index (BMI). Among 100 107 participants screened (46 ± 13 years; 17% women), prevalence of diabetes was 12 571 (15%), hypertension: 30 345 (33%) and overweight: 61 219 (65%). Diabetes was treated more often than hypertension (44% vs 11%). Hypertension and diabetes prevalence values were relatively high in young obese adults; BMI correlated significantly (\( p < .001 \)) stronger to both systolic BP and RBG for subjects younger than 40 years than for those who were older (\( r = 0.27 \) vs \( r = 0.06 \) and \( r = 0.15 \) vs \( r = 0.03 \), respectively). Among obese women aged 60 years and older the hypertension prevalence was higher than 40%, in obese men this prevalence value was already seen from the group of 30 to 40 years old. For participants older than 50 years with hypertension, diabetes prevalence was 20%. These results show that screening initiatives like these are highly needed to increase the overall awareness of diabetes and particularly of hypertension. Systematic screening programs also help to identify specific patient populations and cope with undertreatment of those at the highest cardiovascular risk. The fact that women were underrepresented in the present screening campaign suggests actions are needed to encourage them to participate in health care programs.

KEYWORDS
cardiovascular risk, diabetes, hypertension, obesity, screening

1 INTRODUCTION

India is a rapidly developing country; this has led to a rapid change from reduction in communicable diseases to an increase in non-communicable diseases. Following this, cardiovascular diseases have become the number one cause of death, and responsible for a quarter of all mortality.1 This number is still increasing due to factors related to developing such as industrialization, urbanization, and changes in lifestyle, so-called epidemiological transition.2 A nationally representative study among 1.3 million Indians showed prevalence values of
diabetes and hypertension of 7.5% and 25%, respectively. In addition, the prevalence of people with diabetes in India had increased from 26 million in 1990 to 65 million in 2016 with a prevalence of 12% in those older than 50 years of age. Consequently, cardiovascular diseases are responsible for a massive economic burden with estimated costs of $2.17 trillion between 2012 and 2030 being the major cause of the economic loss. However, despite these high figures, awareness of both diabetes and hypertension is still low among Indians.

Public screening activities may help to increase awareness of cardiovascular diseases that are often symptomless and may improve the insight into the prevalence of these diseases and its control. Following this, an initiative was undertaken to set up health care screening booths in eight airports and one hospital around India. The current paper presents the obtained data of more than 100,000 participants screened for cardiovascular risks.

2 | METHODS

2.1 | Study design and participants

The study design envisaged a retrospective analysis of a database created from a community-based screening campaign focusing on blood pressure (BP), blood glucose measurement and body mass index (BMI), and the collection of basic information.

Data were obtained in the period between August 2019 and March 2020. A visible temporary booth was established at 8 airports (Ahmedabad, Cochin, Coimbatore, Delhi Metro, Goa, Lucknow, Mumbai, and Trivandrum) and one hospital (KG Hospital Coimbatore).

Approval for this retrospective study was obtained from Ripon Independent Ethics Committee (RIEC), Chennai, India. A digital signature was obtained from each participant while data were electronically collected using a tablet. Data from the participants were collected in a non-identifiable manner to protect the privacy of all participants. The number of participants screened per state of India can be found in Figure Supplement S1.

2.2 | Participants

The screened population consisted of an unselected sample of 101,982 participants. Since most of the screening was done at the airport, the visitors could come from anywhere. However, it appeared that only 0.8% (817) of all visitors were non-Indians. As the present analysis was aimed at improving the insight into the prevalence of cardiovascular diseases in India, non-Indians were excluded from the analysis for the present study. A table in which the characteristics of subjects from “elsewhere” were compared to those with residence in India are shown in the Table S1. In total, 100,107 Indian participants were analyzed for the present study (see Figure 1, flow chart).

2.3 | Booth visit

When entering the booth to be measured the following participant’s characteristics were registered: sex, age, nationality, city of residence, profession, and flying frequency. In addition, participants were asked if hypertension or diabetes was diagnosed previously and in all except three booths (Cochin, Coimbatore, Delhi Metro), it was registered if participants received treatment for either one of these conditions.

2.4 | Measurements

2.4.1 | Blood pressure measurement

The booth attendants were well trained to take BP and blood glucose readings as per routinely followed protocols at clinic or lab. BP was measured with a validated oscillometric BP monitor that automatically measured 3 times in a row with 15-s interval times and provided the average of three BP readings (Circa 120/80, Watch BP Home A, Eris Ahmedabad). Patients were measured in a sitting position, with their back supported and the arm supported at heart level. Participants were instructed not to talk during BP measurement and keep their legs uncrossed with both feet flat on the floor. A cuff-size was selected appropriate to the participant’s arm circumference (small size cuffs for upper arm circumferences between 14 and 22 cm, medium size 22–32 cm, large size 32–42 cm, and extra-large size 32–52 cm).

2.4.2 | Blood glucose measurement

After the BP measurement had been taken, blood glucose was determined using the Accu-Chek Performa blood glucose monitor (Roche, Germany). Participants were asked when they had last eaten. If the participant reported not to have eaten within the last 8 h their glucose value was considered as Fasting Blood Glucose (FBG), all other values were considered Random Blood Glucose (RBG).
Thereafter, participants were asked to take off their shoes for measuring their height (Thermocare, height measurement scale) and weight (Omron weighing scale) to assess BMI.

Results were discussed with the participant and appropriate advice followed the obtained measurements (for example, participants were recommended to visit their doctor if the values obtained fell outside the normality range). Finally, a printed report was handed to the participants or sent by SMS if this was preferred (see Figure S2).

2.5 Statistical analysis

Participants were classified as hypertensive if the average of three BP readings was equal to or higher than 140 mmHg and/or 90 mmHg for systolic and diastolic BP. Subsequently, BP values were categorized according to ESH/ESC standards: (Optimal < 120 and < 80 mmHg, Normal 120–129 and 80–84 mmHg, High normal 130–139 mmHg and 85–89 mmHg Grade 1 hypertension: 140–159 and 90–99 mmHg, Grade 2 hypertension 160–179 and 100–109 mmHg, Grade 3 hypertension: ≥180 and ≥110 mmHg for systolic and diastolic blood pressure, respectively). For classifications in glucose ranges guidelines of the American Diabetes Association were applied. For FBG a level of ≥ 126 mg/dL and for RBG a value ≥ 200 mg/dL was labeled as diabetes. Weight was divided in 6 classes (underweight, BMI less than 18.5 kg/m²; normal, 18.5–24.9 kg/m²; overweight, 25.0 to 29.9 kg/m²; class I obesity 30–34.9 kg/m², class II obesity 35–39.9 kg/m², class III obesity 40 kg/m² or higher). Prevalence for overweight (yes, no [≥ 25.0 kg/m²]) and obesity (yes, no [≥ 30.0 kg/m²]) were determined and used for comparison. Participants were divided in age groups of less than 30 years old with stepwise 10-years increases until 60 years and older. Participant’s characteristics were compared for sex and other aspects such as screening location (hospital vs airports), BP and weight class. Main demographic and clinical data were summarized by calculating the mean (±SD) in case of continuous variables and the absolute (n) and relative (%) frequency in case of categorical variables. Differences across groups were evaluated using retrospective analysis of variance (ANOVA). For categorical variables, differences across groups were evaluated using Chi-square tests. We calculated the prevalence of hypertension and diabetes for categories of age, BP (for diabetes prevalence), and BMI. To determine the statistical relationship between systolic BP and age and other measured parameters, Pearson’s correlation coefficients (CCs) and confidence intervals were calculated. In order to verify if Pearson’s CCs would differ between groups younger and older than 40 years of age, CCs were calculated for systolic BP and BMI and RBG and BMI and compared for significant differences. No methods for imputation were performed. Results were presented in p-values if considered relevant, a p value of < .01 was considered significant. Analyses were performed using the statistical package R Studio Version 1.2.5033 for Windows.

3 RESULTS

Data from 100 107 Indian visitors were collected with an average age of 45.9 ± 12.9 years. Among these, there were 8599 (8.6%) who did not undergo BP measurement and 15 203 (15.2%) participants had no blood glucose measurement.

Table 1 shows the unweighted characteristics of all booth visitors and separated for sex (17% female). In total, 30 345 (33.2%) had hypertension and 12 571 participants (14.8%) were classified as diabetes (388 [19.4%] based on FPG and 12183 [14.7%] based on RBG). Weight and height measurements showed an average BMI of 26.7 ± 4.0 kg/m², 61219 (64.8%) participants were overweight, and 17074 (18.1%) were obese.

Males were slightly older than females (46.0 ± 12.6 vs 45.3 ± 13.8 years), had higher BMI (26.7 ± 3.9 vs 26.3 ± 4.5 kg/m²), higher RBG (147.9 ± 65.1 vs 139.1 ± 58.6 mg/dL), and higher systolic and diastolic BP values (131.0/83.6 vs 123.4/76.6 mmHg, all p < .001). In contradiction to the higher BMI for males, females showed higher obesity prevalence than males (19.5% vs 17.8% p < .001).

Of all participants 1,428 individuals were measured at a booth located at a hospital entrance hall, their characteristics slightly differed from the airport booth visitors (Table S2).

Table 2 shows that systolic BP had highest correlation values with age (r = 0.27), glucose (r = 0.17), and BMI (r = 0.16). FBG showed a stronger correlation with age (r = 0.29) and BMI (r = 0.16) than RBG (r = 0.22 and r = 0.09, respectively).

3.1 Treatment

Among participants whose measured blood glucose value suggested diabetes and who were asked for their treatment, 44% (n = 4131) reported to be treated for diabetes (Table 3). For those measured with elevated BP 11% (n = 2599) reported to receive antihypertensive treatment. Of the participants treated for diabetes 46% (n = 3574 out of n = 7705) had normal glucose values, whereas 56% (n = 3282 out of n = 5881) of those treated for hypertension measured normal BP values. Of the participants whose measured BP value classified them as having grade 3 hypertension (n = 1383), only 15.1% received antihypertensive treatment (Table S3).

3.2 Prevalence values of hypertension and diabetes

Stratification by age-groups and BMI classes and separated for sex, showed a similar trend in hypertension prevalence for both males and females (Figure 2, top), although males showed higher values overall. Hypertension prevalence increased with higher BMI classes and showed a stepwise increase with each age-group. High BMI had a major effect on hypertension at younger age in both males and females, in the age groups younger than 40 years old the hypertension prevalence
## Table 1
Subject characteristics separated for sex

|                      | Female (No. = 17,321) | Male (No. = 82,786) | Total (No. = 100,107) | p     |
|----------------------|------------------------|----------------------|------------------------|-------|
| **Age [y]**          |                        |                      |                        | < .001|
|                      | 45.3 (13.8)            | 46.0 (12.6)          | 45.9 (12.9)            |       |
| **Systolic BP [mmHg]** |                        |                      |                        | < .001|
|                      | 123.4 (18.7)           | 131.0 (16.6)         | 129.7 (17.2)           |       |
| **Diastolic BP [mmHg]** |                      |                      |                        | < .001|
|                      | 76.7 (10.7)            | 83.6 (10.6)          | 82.4 (11.0)            |       |
| **Heart Rate [BPM]**  |                        |                      |                        | < .001|
|                      | 84.9 (12.8)            | 85.5 (13.6)          | 85.4 (13.5)            |       |
| **Random Blood Glucose [mg/dL]** |            |                      |                        | < .001|
| (no. = 82,907)       | 139.1 (58.6)           | 147.9 (65.1)         | 146.5 (64.2)           |       |
| **Fasting Plasma Glucose [mg/dL]** |              |                      |                        | .053  |
| (no. = 1997)         | 108.0 (23.8)           | 110.4 (24.6)         | 110.0 (24.5)           |       |
| **Height [cm]**      |                        |                      |                        | < .001|
|                      | 158.9 (6.4)            | 170.7 (7.2)          | 168.6 (8.3)            |       |
| **Weight [kg]**      |                        |                      |                        | < .001|
|                      | 66.5 (12.0)            | 78.0 (12.5)          | 75.9 (13.2)            |       |
| **Body Mass Index [kg/m²]** |                  |                      |                        | < .001|
|                      | 26.3 (4.5)             | 26.7 (3.9)           | 26.7 (4.0)             |       |
| **Overweight**       |                        |                      |                        | < .001|
| Non-Overweight       | 6688 (40.6%)           | 26,548 (34.0%)       | 33,236 (35.2%)         |       |
| Overweight           | 9780 (59.4%)           | 51,439 (66.0%)       | 61,219 (64.8%)         |       |
| **Obesity**          |                        |                      |                        | < .001|
| Non-Obese            | 13,261 (80.5%)         | 64,120 (82.2%)       | 77,381 (81.9%)         |       |
| Obese                | 3207 (19.5%)           | 13,867 (17.8%)       | 17,074 (18.1%)         |       |
| **Random Blood Glucose** |                    |                      |                        | < .001|
| Diabetes             | 1463 (10.8%)           | 10,720 (15.5%)       | 12,183 (14.7%)         |       |
| Non-Diabetes         | 12,138 (89.2%)         | 58,586 (84.5%)       | 70,724 (85.3%)         |       |
| **Fasting Plasma Glucose** |                |                      |                        | .088  |
| Diabetes             | 54 (16.1%)             | 334 (20.1%)          | 388 (19.4%)            |       |
| Non-Diabetes         | 282 (83.9%)            | 1327 (79.9%)         | 1609 (80.6%)           |       |
| **Blood pressure diagnosis** |              |                      |                        | < .001|
| Hypertension         | 3470 (21.9%)           | 26,875 (35.5%)       | 30,345 (33.2%)         |       |
| Normotension         | 12,399 (78.1%)         | 48,765 (64.5%)       | 61,164 (66.8%)         |       |
| **Diabetes total**   |                        |                      |                        | < .001|
| DM                   | 1517 (10.9%)           | 11,054 (15.6%)       | 12,571 (14.8%)         |       |
| non-DM               | 12,420 (89.1%)         | 59,913 (84.4%)       | 72,333 (85.2%)         |       |
| **Tachycardia [≥100 BPM]** |                 |                      |                        | < .001|
| Normal               | 13,829 (87.5%)         | 64,014 (85.0%)       | 77,843 (85.4%)         |       |
| Tachycardia          | 1967 (12.5%)           | 11,338 (15.0%)       | 13,305 (14.6%)         |       |
| **Hypertension awareness** |               |                      |                        | < .001|
| No                   | 16,405 (94.7%)         | 77,748 (93.9%)       | 94,153 (94.1%)         |       |
| Yes                  | 916 (5.3%)             | 5038 (6.1%)          | 5954 (5.9%)            |       |

(Continues)
TABLE 1 (Continued)

|                        | Female (No. = 17321) | Male (No. = 82786) | Total (No. = 100107) | p   |
|------------------------|----------------------|--------------------|----------------------|-----|
| Diabetes awareness     |                      |                    |                      |     |
| No                     | 16360 (94.5%)        | 75727 (91.5%)      | 92087 (92.0%)        | <.001 |
| Yes                    | 961 (5.5%)           | 7059 (8.5%)        | 8020 (8.0%)          |     |
| Receiving treatment    |                      |                    |                      |     |
| Hypertension           | 568 (3.3%)           | 2840 (3.4%)        | 3408 (3.4%)          | <.001 |
| Diabetes               | 600 (3.5%)           | 4865 (5.9%)        | 5465 (5.5%)          |     |
| Both                   | 361 (2.1%)           | 2252 (2.7%)        | 2613 (2.6%)          |     |
| None                   | 15792 (91.2%)        | 72829 (88.0%)      | 88621 (88.5%)        |     |
| Profession             |                      |                    |                      |     |
| Business person        | 662 (4.5%)           | 19444 (26.5%)      | 20106 (22.8%)        | <.001 |
| Corporate Job          | 5354 (36.1%)         | 45648 (62.3%)      | 51002 (57.9%)        |     |
| Education              | 214 (1.4%)           | 819 (1.1%)         | 1033 (1.2%)          |     |
| Government Service     | 611 (4.1%)           | 5278 (7.2%)        | 5889 (6.7%)          |     |
| Home Maker             | 7536 (50.8%)         | 1233 (1.7%)        | 8769 (10.0%)         |     |
| Student                | 458 (3.1%)           | 850 (1.2%)         | 1308 (1.5%)          |     |
| Flying Frequency       |                      |                    |                      |     |
| Occasional             | 13221 (92.6%)        | 55731 (77.2%)      | 68952 (79.7%)        | <.001 |
| Once a month           | 813 (5.7%)           | 12000 (16.6%)      | 12813 (14.8%)        |     |
| Once a week            | 146 (1.0%)           | 2692 (3.7%)        | 2838 (3.3%)          |     |
| Multiple times a week  | 104 (0.7%)           | 1805 (2.5%)        | 1909 (2.2%)          |     |

TABLE 2  Means, standard deviations, and correlations with confidence intervals for the parameters measured

| Variable            | M   | SD  | 1   | 2   | 3   | 4   | 5   | 6   |
|---------------------|-----|-----|-----|-----|-----|-----|-----|-----|
| 1. Age (years)      | 45.87 | 12.90 | 0.11 |
| 2. BMI (kg/m²)      | 26.66 | 4.01  | [0.11, 0.12] |
| 3. Systole (mmHg)   | 129.65 | 17.22 | 0.27 | 0.16 |
|                     | [0.26, 0.28] | [0.15, 0.16] |
| 4. Diastole (mmHg)  | 82.36 | 10.97 | 0.04 | 0.17 | 0.69 |
|                     | [0.03, 0.04] | [0.16, 0.17] | [0.69, 0.70] |
| 5. Heart rate (bpm) | 85.39 | 13.47 | -0.08 | 0.12 | 0.04 | 0.22 |
|                     | [-0.09, -0.08] | [0.11, 0.12] | [0.03, 0.05] | [0.22, 0.23] |
| 6. RBG (mg/dL)      | 146.37 | 64.08 | 0.22 | 0.09 | 0.17 | 0.07 | 0.22 |
|                     | [0.22, 0.23] | [0.08, 0.09] | [0.17, 0.18] | [0.06, 0.08] | [0.21, 0.23] |
| 7. FBG (mg/dL)      | 109.96 | 24.47 | 0.29 | 0.16 | 0.17 | 0.14 | 0.16 | NA |
|                     | [0.25, 0.33] | [0.11, 0.20] | [0.12, 0.21] | [0.09, 0.18] | [0.11, 0.21] |

Note. M indicates mean; SD, standard deviation; FBG, fasting blood glucose; RBG, random blood glucose; NA, not applicable. Values in square brackets indicate the 95% confidence interval for each correlation. All correlation values are significant at p < .01.

Among obese subjects was about twice the prevalence as compared to those with normal BMI. However, this BMI effect seemed to become less with older age. This was confirmed with Pearson correlation analysis showing that systolic BP correlated stronger with BMI in the group younger than 40 years of age than in the group of 40 years and older ($r = 0.27$ vs $r = 0.06$, $p < .0001$, respectively).

Among obese (BMI > 30 kg/m²) women aged 60 years and older more than 40% were hypertensive, whereas for obese men a similar
A similar trend as for hypertension prevalence was seen for diabetes prevalence (Figure 2, middle). Diabetes showed a clear stepwise increase with each higher age-group. Similar as for hypertension the diabetes prevalence seemed to increase more with higher BMI classes at younger age than at older age. This was confirmed with Pearson correlation analysis that showed that RBG had a higher correlation with BMI for those younger than 40 years of age, as compared to those 40 years and older ($r = 0.15$ vs $r = 0.03$, $p < .0001$, respectively).

Categorization for BP classes and age groups showed a similar stepwise and predictive increasing trend with diabetes prevalence (Figure 2, bottom). Overall, males showed higher diabetes prevalence values than females, but this difference was not as large as was seen for hypertension. When aged older than 50 years and classified hypertension grade 1 or higher both males and females showed a diabetes prevalence of 20% or more.

### DISCUSSION

The present retrospective analysis from data of 100,107 participants screened showed that one-third had hypertension, 15% had diabetes, and 18% of all participants were obese (65% being overweight). Among...
When screening at the airport? 

The idea for taking this screening initiative was triggered by the "May Measurement Month” initiative, a global campaign set up to raise awareness of hypertension and to improve blood pressure screening facilities in those parts of the world where such facilities are particularly poor. Within this initiative it is highlighted that for screening sites a wide range of locations may be considered. In order to cover a wider spectrum of cardiovascular diseases measurements were expanded for assessing blood glucose and BMI.

The departure hall of an airport appears to be an excellent place for retail business because one can reach a high number of people. This nowadays particularly applies to India. Due to rapid changes in the economy, infrastructure and the start of many low-cost airlines, Indian air traffic has increased quickly. From 2014 to 2019, the number of passengers handled at airports in India increased from 169 million to 345 million. Interestingly, whereas the number of international flight passengers only increased by 50% during this time, the number of domestic flights increased by more than 300% to 275 million passengers in 2019. Because more than 80% of all flights in India are domestic, it is not surprising that also the majority of the population screened in the present paper also had an Indian nationality.

The overall aim of this screening set-up was to increase cardiovascular risk awareness, which basically does not differ much from the aim of creating brand awareness that most retail stores at the airport have. The reason that this has proven its value is because, next to the high number of visitors, the store opening times at airports has a much longer time span than the normal markets. This benefit was recognized
for the present screening campaign, with more than 8000 individuals screened before 8 h am and almost 4500 between 9 and 10 h PM.

In addition, airport visitors can easily spend an hour or more in the departure hall with less distraction than usual. During that time, people may be more willing than usual to participate in a screening event that could easily take 20 min of their time. Finally, because people have more time to waste, they may experience less stress than usual. This may have a positive effect on the examination, especially for blood pressure measurement.

4.3 | Strengths and limitations of the study

The strength of the present retrospective analysis lies in the high number of participants who were screened and the fact that the screening was performed by well-trained technicians. BP measurement was performed in triplicate with a validated oscillometric device. One may argue that hypertension cannot be diagnosed by a one-time triplicate measurement, which is true. Nevertheless, we believe that these figures clearly suggest undertreatment of hypertension for two reasons; First, the figures from the present screening confirm earlier results. Second, among participants with the highest BP (grade 3), who are unlikely to be normotensive, still only 15% of this group received anti-hypertensive drugs.

Blood glucose was measured using a blood glucose meter, although the blood glucose monitor may be considered reliable, the manner of testing is not the gold standard for diagnosing diabetes, and therefore the classification “diabetes” based on the measured value might not be appropriate. However, RBG level equal to and above the range of 200 mg/dL has shown to provide good discrimination for follow-up diagnosis. The present paper also contains data from hospital visitors, this population clearly deviated from the airport visitors and suggests that these were hospital patients with higher cardiovascular risk, but this was not verified. As the hospital visitors represent only 1.4% of the screening participants, their influence on the overall results is minimal. For statistical analysis we did not adjust for screening location and state of living as this was not within the scope of present paper. However, there are some differences in BMI, blood glucose, and blood pressure values between some states of India as can be seen in Figure S3. There was a large difference in the number of males and females who were screened. A reason for this might be that, next to the reason we have explained earlier, airports are often visited by business people who are, certainly in India, more often male. Finally, although the economic situation is quickly improving, India has a skewed economic distribution. Flight tickets can be relatively cheap, certainly when these are domestic and 80% of the participants screened reported to fly only occasionally, but still most Indians cannot afford plane tickets so that the present data from airport visitors may not be considered as nationally representative. However, the study of Geldsetzer and associates showed that being part of the richest household wealth quintile compared with being in the poorest quintile was associated with only a modestly higher probability of diabetes (2.81 and 3.47 percentage points for rural and urban, respectively) and hypertension (4.15 and 3.01 percentage points for rural and urban, respectively). In addition, education level appeared to have minor influence. This is important information for the interpretation of the results from the present screening as most participants may belong to the richest household quintile of India and have relatively high educational level.

5 | CONCLUSION

Although, the sample may not be considered as nationally representative, the big data provided important information that may be used for influencing screening policy and the management of cardiovascular diseases in India. The present screening initiative revealed a high prevalence of important cardiovascular risk factors. In addition, it showed a low level of awareness and treatment of diabetes and for hypertension. However, the treatment level for diabetes was higher than for hypertension (44% vs 11%). These results show that Screening initiatives like these are needed to increase overall awareness of diabetes and particularly of hypertension. Systematic screening programs also help to identify specific patient populations and cope with undertreatment of those at highest cardiovascular risk. For example, the present study showed that the prevalence of diabetes was higher than 15% and 20% and the hypertension prevalence was higher than 25% and 40% in overweight men and women aged 50 years and older, respectively. In addition, both diabetes and hypertension prevalence values were relatively high in young adults with obesity. These findings indicate that preventive health care strategies focusing on these groups would be most efficient to improve cardiovascular health. Finally, the fact that women were underrepresented in the present study suggests that actions are needed to encourage them, in particular, to participate in health care programs.

ACKNOWLEDGEMENTS

Eris Foundation an NGO (A non-Government Charitable organization) established the booths in all airports and the one hospital. Eris Life-sciences Ltd. Supported with the logistics of the screening

CONFLICTS OF INTEREST

WJV is an employee of Microlife corporation, Taipei, Taiwan
NG is an employee of Eris Lifesciences Ltd.

AUTHOR CONTRIBUTIONS

WJV analyzed data, wrote manuscript, and prepared the figures.
NG, guided the screening project, collected the data, and reviewed the manuscript.

ORCID

Willem J. Verberk Ph.D. https://orcid.org/0000-0003-2230-0488

REFERENCES

1. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India. Circulation. 2016;133:1605–1620.
2. Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Ann Global Health. 2016;82:307.
3. Geldsetzer P, Manne-Goehler J, Theilmann M, et al. Diabetes and hypertension in India: a nationally representative study of 1.3 million adults. JAMA Intern Med. 2018;178:363–372.

4. Tandon N, Anjana RM, Mohan V, et al. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Global Health. 2018;6:e1352-e62.

5. National Diabetes and Diabetic Retinopathy Survey India, 2015-2019 A summary report, National Programme for Control of Blindness & Visual Impairment, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi. https://npcbvi.gov.in/

6. Bloom DE, Cafiero-Fonseca ET, Candeias V, et al. Economics of Non-Communicable Diseases in India: The Costs and Returns on Investment of Interventions to Promote Healthy Living and Prevent, Treat and Manage NCDs. World Economic Forum, Harvard School of Public Health; 2014.

7. Deepa M, Bhansali A, Anjana RM, et al. Knowledge and awareness of diabetes in urban and rural India: the Indian Council of Medical Research India Diabetes Study (Phase I): Indian Council of Medical Research India Diabetes 4. Indian J Endocrinol Metab. 2014;18:379–385.

8. Devi P, Rao M, Sigamani A, et al. Prevalence, risk factors and awareness of hypertension in India: a systematic review. J Hum Hypertens. 2013;27:281–287.

9. Stergiou GS, Giovas PP, Gkinos CP, Patouras JD. Validation of the Microlife WatchBP Home device for self home blood pressure measurement according to the International Protocol. Blood Press Monit. 2007;12:185–188.

10. Clark K, Snowball O, Nzelu D, Kay P, Kametas NA. Validation of the Microlife WatchBP Home blood pressure device in pregnancy for medium and large arm circumferences. Blood Press Monit. 2018;23:171–174.

11. Chung Y, de Greeff A, Shennan A. Validation and compliance of a home monitoring device in pregnancy: microlife WatchBP home. Hypertens Pregnancy. 2009;28:348–359.

12. Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36:1953–2041.

13. Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. Clin Diabetes 2020;38:10-38.

14. Mohan V. Why are Indians more prone to diabetes?. J Assoc Physicians India. 2004;52:468–474.

15. Kaul U, Bhagwat A, Omboni S, et al. Blood pressure and heart rate related to sex in untreated subjects: the India ABPM study. J Clin Hypertens (Greenwich). 2020;22:1154–1162.

16. Kapoor M, Agrawal D, Ravi S, Roy A, Subramanian SV, Guleria R. Missing female patients: an observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India. BMJ Open. 2019;9:e026850.

17. Beaney T, Burrell LM, Castillo RR, et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J. 2019;40:2006–2017.

18. Number of passengers handled at airports in India from financial year 2014 to 2021, by type. https://www.statista.com/statistics/588028/passengers-boarded-by-type-by-indian-air-carriers/

19. Thompson AM, Eguchi K, Reznik ME, Shah SS, Pickering TG. Validation of an oscillometric home blood pressure monitor in an end-stage renal disease population and the effect of arterial stiffness on its accuracy. Blood Press Monit. 2007;12:227–232.

20. Masiero S, Saladini F, Benetti E, Palatini P. Accuracy of the Microlife large-extra large-sized cuff (32-52 cm) coupled to an automatic oscillometric device. Blood Press Monit. 2011;16:99–102.

21. Jin C-N, Yu C-M, Sun J-P, et al. The healthcare burden of hypertension in Asia. Heart Asia. 2013;5:238–243.

22. Rhee MK, Ho Y-L, Raghavan S, et al. Random plasma glucose predicts the diagnosis of diabetes. PLoS One. 2019;14:e0219964.

23. Jeemon P, Séverin T, Amodeo C, et al. World Heart Federation Roadmap for Hypertension – a 2021 update. Global Heart. 2021;16.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.